What A Patient Holder Is Really Paying For CVS Health Stock

The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.

At a glance, CVS Health (CVS) stock looks expensive. Trading around $107, its price-to-earnings ratio on the last twelve months of results is about 46.2 times. For many investors, that’s where the analysis stops. But it shouldn’t.

That same share price tells a very different story once you look at the earnings analysts expect the company to generate two years from now. On those 2027 estimates, the stock’s multiple falls to just 12.7 times. That’s a 73% lower multiple, a steep discount that materializes as projected earnings grow into today’s price. A patient holder is effectively buying the business at that future, lower valuation. It is important to note that the trailing multiple is based on reported GAAP earnings, while forward estimates typically use a non-GAAP basis, so part of this compression reflects a difference in accounting, not just pure growth.

Is That Growth Believable?

The honest question is never the price tag; it is whether the growth that produces this discount is likely to arrive. Here, the consensus forecast seems grounded. Analysts project revenue will grow about 2.2% a year, which is actually well below the 7.6% growth the company delivered over the last twelve months. If CVS can maintain even a fraction of its recent momentum, driven by improvements in its Health Care Benefits segment, the current earnings estimates could prove conservative.

Crucially, Wall Street’s forecast aligns with the company’s own outlook. For the current fiscal year, analysts expect about $7.43 in earnings per share. That figure sits comfortably within management’s own guidance for a range of $7.30 to $7.50 in adjusted EPS. When management and a consensus of 17 analysts are in close agreement, the foundation for that forward discount feels more solid.

And CVS Health is far from alone: which 10 S&P 500 stocks carry the biggest hidden forward discount? Our rankings sort the entire index by how little you are really paying for each name’s growth once the out-year earnings land.

The Price Of A Misstep

Of course, no growth story is a straight line. A stock priced for future earnings can be sensitive to shifts in sentiment. In past market shocks, the stock has fallen as much as 39% from peak to trough. The forward discount rewards patience, but it doesn’t eliminate volatility.

The Real Reward Is Not the Discount

It’s critical to understand how this pays off. If the share price never moves, an investor who buys today will simply end up owning a stock trading at 12.7 times its 2027 earnings. That proves they didn’t overpay, it’s a margin of safety, but it doesn’t produce a gain. The actual reward comes from price appreciation, which requires the market to continue paying a richer multiple as those earnings arrive.

Consider one scenario: if the multiple settles at about 29.5 times those 2027 earnings, roughly halfway between today’s 46.2 times and that 12.7 times floor, the stock would be worth about $247. That implies a potential 132% gain from today’s price. This forward-looking view also helps contextualize the premium on CVS stock vs what its peers deliver.

What You’re Really Buying

The premium you see on CVS stock today is not the price a patient investor is really paying. On the earnings expected by 2027, that same price represents a far more ordinary multiple. Even if the stock stalls, you haven’t necessarily overpaid for the growth. But if the market keeps valuing the company at anything near today’s multiple as those earnings become reality, the share price compounds with them. The key metric to watch is the margin recovery in the Aetna business, which management highlighted as a core driver of its improved outlook. If that continues, the growth behind the discount is on track.

And if it is exposure to U.S. healthcare providers as a whole you want, rather than this one name, a U.S. healthcare providers ETF like IHF covers that theme.

What A Stock Is Worth And How Much To Own Are Different Questions

Valuation says what a stock might be worth; it says nothing about how much of your wealth should ride on it. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.